Search research articles
Contact Us
Filters
Showing results (61-70 of 76) with videos related to
Page
of 8
Sort By:
Molecular Cancer Therapeutics
|
March 9, 2017
Focal Adhesion Kinase as a Potential Target in AML and MDS
Bing Z Carter, Po Yee Mak, Xiangmeng Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 22, 2018
Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in <i>FLT3</i>-Mutant Acute Myeloid Leukemia
Xuejie Jiang, Po Yee Mak, Hong Mu, et al.
Leukemia
|
December 26, 2023
Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia
Hiroki Akiyama, Ran Zhao, Lauren B Ostermann, et al.
Leukemia
|
March 8, 2024
Correction: Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia
Hiroki Akiyama, Ran Zhao, Lauren B Ostermann, et al.
Cancer
|
April 9, 2024
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia
Elias Jabbour, Fadi G Haddad, Koji Sasaki, et al.
Cancer Discovery
|
April 24, 2023
Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Christina Glytsou, Xufeng Chen, Emmanouil Zacharioudakis, et al.
Haematologica
|
November 4, 2021
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill <i>FLT3</i>-ITD acute myeloid leukemia
Sean M Post, Huaxian Ma, Prerna Malaney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2009
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia
Aaron D Schimmer, Elihu H Estey, Gautam Borthakur, et al.
Translational Oncology
|
February 3, 2022
Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML
Kotoko Yamatani, Tomohiko Ai, Kaori Saito, et al.
Leukemia & Lymphoma
|
June 10, 2024
<i>TP53</i> Y220C mutations in patients with myeloid malignancies
Georgina Gener-Ricos, Jan P Bewersdorf, Sanam Loghavi, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 76) with videos related to
Sort By:
Page
of 8
Molecular Cancer Therapeutics
|
March 9, 2017
Focal Adhesion Kinase as a Potential Target in AML and MDS
Bing Z Carter, Po Yee Mak, Xiangmeng Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 22, 2018
Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in <i>FLT3</i>-Mutant Acute Myeloid Leukemia
Xuejie Jiang, Po Yee Mak, Hong Mu, et al.
Leukemia
|
December 26, 2023
Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia
Hiroki Akiyama, Ran Zhao, Lauren B Ostermann, et al.
Leukemia
|
March 8, 2024
Correction: Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia
Hiroki Akiyama, Ran Zhao, Lauren B Ostermann, et al.
Cancer
|
April 9, 2024
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia
Elias Jabbour, Fadi G Haddad, Koji Sasaki, et al.
Cancer Discovery
|
April 24, 2023
Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Christina Glytsou, Xufeng Chen, Emmanouil Zacharioudakis, et al.
Haematologica
|
November 4, 2021
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill <i>FLT3</i>-ITD acute myeloid leukemia
Sean M Post, Huaxian Ma, Prerna Malaney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2009
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia
Aaron D Schimmer, Elihu H Estey, Gautam Borthakur, et al.
Translational Oncology
|
February 3, 2022
Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML
Kotoko Yamatani, Tomohiko Ai, Kaori Saito, et al.
Leukemia & Lymphoma
|
June 10, 2024
<i>TP53</i> Y220C mutations in patients with myeloid malignancies
Georgina Gener-Ricos, Jan P Bewersdorf, Sanam Loghavi, et al.
Page
of 8